Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sagimet Biosciences Inc.

9.50
-0.3300-3.36%
Volume:430.12K
Turnover:4.10M
Market Cap:305.86M
PE:-5.35
High:9.99
Open:9.85
Low:9.25
Close:9.83
Loading ...

Sagimet Biosciences price target lowered to $25 from $30 at Oppenheimer

TIPRANKS
·
13 May

Sagimet Biosciences Reports Q1 2025 Financial Results

TIPRANKS
·
10 May

JonesTrading Keeps Their Buy Rating on Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
10 May

Sagimet Biosciences Q1 2025 EPS $(0.56) Beats $(0.65) Estimate, Cash, Cash Equivalents And Marketable Securities As Of March 31, 2025, Were $144.6M

Benzinga
·
08 May

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

THOMSON REUTERS
·
08 May

Top Penny Stocks To Watch In April 2025

Simply Wall St.
·
25 Apr

Holding(s) in Company

GlobeNewswire
·
23 Apr

ProQR Appoints Dennis Hom as CFO, Cristina Lopez as CMO

MT Newswires Live
·
14 Apr

Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position

TIPRANKS
·
14 Mar

Sagimet Biosciences Price Target Announced at $32.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom

TIPRANKS
·
13 Mar

Sagimet Biosciences Advances MASH Treatment with New Trials

TIPRANKS
·
13 Mar

Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Mar

Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567

TIPRANKS
·
12 Mar

Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials

MT Newswires Live
·
11 Mar

Sagimet Biosciences receives FDA nod to begin testing its therapy for acne

Reuters
·
11 Mar

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

GlobeNewswire
·
11 Mar

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?

Insider Monkey
·
25 Feb

BRIEF-Sagimet Biosciences Announces Oral Presentation At The Mash Pathogenesis And Therapeutic Approaches Keystone Symposium

Reuters
·
19 Feb

Sagimet Biosciences Announces Oral Presentation at the Mash Pathogenesis and Therapeutic Approaches Keystone Symposium

THOMSON REUTERS
·
19 Feb